Apimeds Pharmaceuticals US, Inc.
AAMEX:APUSCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vinod Menon
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 100 Matawan Rd Matawan NJ United States 07747
- IPO Date
- May 9, 2025
- CIK
- 0001894525
- Website
- apimedsus.com
- Similar Companies
- Business
- Apimeds Pharmaceuticals US, Inc. operates as a clinical-stage biopharmaceutical enterprise within the United States. The company is dedicated to the research, development, and eventual commercialization of Apitox, a unique intradermally administered compound derived from purified honeybee venom. This investigational biologic is primarily being advanced through Phase III clinical trials for managing inflammation and pain associated with knee osteoarthritis. Additionally, Apimeds is conducting non-registered corporate sponsorship studies to explore its potential applications for multiple sclerosis. The company, which commenced operations in 2020, recently completed its Initial Public Offering in May 2025, with shares now trading on the NYSE American under the ticker "APUS." Apimeds Pharmaceuticals US is located in Matawan, New Jersey, and operates with a licensing agreement for Apitox from Apimeds Korea, where a similar product has been in use.
Company News
NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide
MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure
MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media
Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?
MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits
IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.
NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October
For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business